Considerations for Polymers Used in Ocular Drug Delivery

Area of Science:

• Ophthalmic drug delivery
• Biomaterials science
• Polymer chemistry

Background:

• Age-related eye diseases, including glaucoma, age-related macular degeneration (AMD), and cataracts, are increasing.
• Current treatments involve eye drops, injections, or tissue replacement, with limitations in efficacy and patient compliance.
• Polymers are being explored for sustained drug release to enhance ocular treatment outcomes.

Purpose of the Study:

• To review synthetic and biopolymers for ocular drug delivery, focusing on FDA-approved materials.
• To discuss polymer synthesis, administration techniques, and their impact on drug release.
• To identify challenges and opportunities in translating polymer-based ocular drug delivery systems to clinical practice.

Main Methods:

• Overview of prevalent synthetic and biopolymers in ocular delivery.
• Discussion of polymer types, synthesis, and administration methods.
• Listing and comparison of FDA-approved polymers with those in literature.

Main Results:

• Polymers enhance ocular drug delivery by improving solubility, pharmacokinetics, and release duration.
• Various polymer classes (synthetic, biopolymer, combinations) offer distinct benefits and challenges.
• Polymer synthesis and processing significantly influence ocular drug release profiles.

Conclusions:

• Polymers have a long history in ocular implants and offer tunable properties for innovative drug delivery.
• Emerging polymer-based systems show promise for treating ocular diseases with improved sustained release.
• Addressing challenges in polymer selection and application is crucial for successful clinical translation.